Drugs / CRB-701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06265727 | Apr 2024 → Jan 2027 expected | cancer | Corbus Pharmaceuticals Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) RECEIVES U.S. FDA CLEARANCE FOR THE REGISTRATIONAL TRIAL FOR THE SECOND-LINE TREATMENT OF OROPHARYNGEAL CANCER irasia.com ↗ |
| 2026-07-28 | Corbus Pharmaceuticals Inc. | Regulatory Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer corbuspharma.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line (2L) oropharyngeal squamous cell carcinoma (OPSCC). |
| 2026-05-26 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers corbuspharma.com ↗
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study ( NCT06265727) of CRB-701 (SYS6002), a next-generation Nectin-4 targeted antibody drug conjugate (ADC). |
| 2025-10-18 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 corbuspharma.com ↗
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC |
| 2025-09-16 | Corbus Pharmaceuticals Inc. | Regulatory FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma corbuspharma.com ↗ |
| 2025-02-14 | Corbus Pharmaceuticals Inc. | Results CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 corbuspharma.com ↗ |
| 2024-12-04 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - CRB-701 (SYS6002) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA irasia.com ↗
CRB-701 (SYS6002) GRANTED FAST TRACK DESIGNATION BY THE U.S . FDA |
| 2024-12-03 | Corbus Pharmaceuticals Inc. | Regulatory FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer corbuspharma.com ↗ |
| 2024-06-01 | Corbus Pharmaceuticals Inc. | Results SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 corbuspharma.com ↗
The poster presents data as of the end of April 2024 from the dose escalation spanning 7 dose levels (0.2, 0.6, 1.2, 1.8, 2.7, 3.6 & 4.5 mg/Kg Q3W) and PK cohorts (2.7 and 3.6 mg/Kg). |
| 2024-01-26 | Corbus Pharmaceuticals Inc. | Results CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 corbuspharma.com ↗
A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses -2 unconfirmed and one non-responding participant with no-nectin-4 expression) and a disease control rate of 71%. |
| 2023-10-16 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701 corbuspharma.com ↗
CRB-701 demonstrates statistically significant tumor growth inhibition in preclinical models that express mid- and high-levels of nectin-4, similar to EV. |
| 2023-08-08 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update corbuspharma.com ↗
Preliminary clinical data generated to date demonstrates a differentiated pharmacokinetic profile relative to other Nectin-4 targeting agents. |
All press releases naming this drug 26 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRB-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265727 ↗ |
| Modality | Other / unclassified | “Nectin-4 targeted Antibody Drug Conjugate (ADC)” NCT06265727 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06265727 ↗ |